Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-07-01
Item 2.02
The filing discloses Greenbrier's third fiscal quarter financial results for the period ended May 31, 2026, including revenue of $576.5M, net earnings of $18.9M ($0.60 diluted EPS), and EBITDA of $69.1M. The earnings release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for quarterly earnings disclosures. Material metrics such as gross margin improvement (230 basis points sequentially), lease fleet growth to 20,600 units, and updated fiscal 2026 guidance are disclosed.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-01
Item 2.02
Franklin Covey disclosed its third quarter fiscal 2026 financial results on July 1, 2026, reporting consolidated revenue of $67.8 million, net income of $3.1 million (versus a prior-year loss), Adjusted EBITDA of $8.3 million with 14% growth, and revised full-year fiscal 2026 guidance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
MSD Investment Corp. issued 9,574,468 shares of common stock for approximately $225.0 million on June 26, 2026, pursuant to subscription agreements with stockholders. The issuance was made under Section 4(a)(2) of the Securities Act and Regulation D, relying on accredited investor representations. This is a classic unregistered equity issuance under Item 3.02, representing a material capital raise that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-01
Item 8.01
GATX exercised a call option on June 30, 2026 to acquire an additional interest in Blocker, thereby increasing its indirect ownership in the JV from 30% to approximately 33.535%. This represents a material acquisition activity under a pre-existing Call Option Agreement, with corresponding amendments to governance and capital provisions in the Blocker LLC Agreement. The transaction materially increases GATX's ownership stake and control rights in the joint venture.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 5.02
Ravi Thanawala was appointed as Executive Vice President and Chief Financial Officer effective August 3, 2026, with a compensation package including $1M base salary, $2.5M in target equity grants, and a $1M sign-on bonus. Michael Mathias transitioned to a non-officer Strategic Advisor role.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-01
Item 8.01
The Board declared a monthly dividend of $0.13589041 per share (reflecting a targeted annualized dividend of $1.60 per share) with a record date of July 31, 2026 and payment date of August 14, 2026. This is a routine but material dividend declaration by a REIT, which is a standard capital distribution to shareholders and would affect investor assessment of the company's capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 8.01
The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-01
Item 2.02
This is a clear earnings release disclosing Culp Inc.'s fourth quarter and full fiscal year 2026 financial results. The Item 2.02 filing explicitly states "Culp, Inc. issued a news release to announce financial results for its fourth quarter and fiscal year ended May 3, 2026," with the full press release attached as Exhibit 99.1. The disclosure includes consolidated net sales, gross profit, operating loss, net loss per share, and segment performance metrics, along with forward guidance for fiscal 2027.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-01
Item 1.01
Kohl's entered into Amendment No. 2 to its Revolving Credit Facility on June 30, 2026, which extends the maturity date by five years to June 30, 2031 and modifies pricing terms and borrowing base provisions. While this is technically an amendment to an existing credit facility rather than a new debt issuance, it represents a material modification of a direct financial obligation that extends the company's debt maturity profile and alters borrowing terms. This falls under debt_issuance as the most appropriate category for creation or material amendment of direct financial obligations, though the amendment nature (rather than new issuance) creates some ambiguity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-01
Item 1.01
Jade Biosciences entered into a material exclusive license agreement with Paragon Therapeutics on June 29, 2026, granting worldwide rights to develop and commercialize monospecific antibodies targeting an undisclosed therapeutic target. The agreement involves up to $22.0 million in development milestones and up to $20.1 million in sublicensing fees, plus royalties on future net sales. This is a strategic operational and commercial transaction material to the company's pipeline and business development, but does not constitute a merger, acquisition, or change of control (which would be classified as ma_activity), nor does it fit other specific financial or governance categories.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-01
Item 1.01
Nasdaq entered into an Amended and Restated Credit Agreement on June 30, 2026, establishing a $1.5 billion senior unsecured five-year revolving credit facility with Bank of America as administrative agent. This represents creation of a new direct financial obligation and material credit arrangement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-01
Item 5.07
Aon held its Annual Meeting of Shareholders on June 26, 2026, with voting results on seven proposals including election of 13 directors (approved), an advisory vote on executive compensation (not approved), ratification of auditors, and authorizations for share issuance and pre-emption rights.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-01
Item 8.01
The Board approved an increase to Aon's share repurchase program by $7.5 billion, bringing total authorization to approximately $8.3 billion, representing a material capital return to shareholders.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-01
EX-99.1
The announcement discloses compensatory arrangements agreed with Ron Edmonds in connection with his appointment as Interim Chief Financial Officer, including a USD$450,000 pro-rated base salary, short-term incentive up to 100% of fixed remuneration, and long-term incentive of USD$95,000 in director share rights subject to shareholder approval. This is a classic executive compensation disclosure under Item 5.02(e) equivalent, material to investors assessing executive costs and governance.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-01
Item 4.01
The filing discloses the dismissal of Deloitte & Touche LLP as the Company's independent registered public accounting firm on June 26, 2026, and the engagement of Cherry Bekaert LLP as the successor auditor. While the auditor reports contained no adverse opinions or disclaimers, they included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern, and material weaknesses in internal control over financial reporting remained unremediated as of December 31, 2025. This is a clear auditor change under Item 4.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-01
Item 1.01
The Company entered into an underwriting agreement on June 29, 2026 for the issuance and sale of $350 million aggregate principal amount of 6.100% Notes due 2031. This is a material creation of a direct financial obligation through debt issuance, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The size ($350M) and nature of the obligation (senior notes) make this material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
Ambarella held its Annual Meeting of shareholders on June 26, 2026, with voting results on four matters: election of three Class II directors (Bryant, Richardson, Schwarting), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
Maurice Tulloch was appointed to the Board of Directors of Reinsurance Group of America, effective July 1, 2026. Tulloch is the former CEO of Aviva Group and brings extensive executive and operational expertise to strengthen the Board's oversight and global perspective.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-01
Item 1.01
Avalyn Pharma entered into a First Amendment to a sublease agreement expanding the leased premises from 8,774 to 13,708 rentable square feet with an increase in future minimum lease payments of approximately $924,000 over the remaining lease term. This is a material operational/real estate commitment that does not fit the specific categories of M&A, debt issuance, or other named financial events, making it an operational business arrangement material to investors assessing the company's capital commitments and facility footprint.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-07-01
Item 8.01
Talos Production Inc., a wholly owned subsidiary of Talos Energy, priced an offering of $800 million in aggregate principal amount of 8.000% second-priority senior secured notes due 2034, with net proceeds intended to fund a pending Gulf of America acquisition, redeem existing 2029 Notes, and pay related fees. The offering is expected to close on or about July 13, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This Item 5.07 disclosure reports the results of Quest Resource Holding Corp's 2026 Annual Meeting of Stockholders held on June 30, 2026, including voting outcomes on five proposals: election of two Class II directors, advisory vote on named executive officer compensation, ratification of auditor Semple, Marchal and Cooper, LLP, amendment to the 2024 Incentive Compensation Plan to increase shares by 600,000, and amendment to the 2024 Employee Stock Purchase Plan to increase shares by 150,000. All matters were approved by requisite stockholder vote, with detailed vote tallies provided for each proposal and director nominee.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-07-01
The 6-K announces a board-approved share repurchase program authorizing up to $10,000,000 in Class A ordinary share repurchases over 18 months, capped at 20% of outstanding shares. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return-of-capital program. The $10 million authorization and 20% cap represent material capital allocation decisions that would affect a reasonable investor's assessment of the company's capital strategy.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-01
The 6-K discloses results of a Class A Meeting and 2026 Annual Meeting of Shareholders held on June 29, 2026, with voting tallies for seven proposals including director elections, auditor ratification, share issuance and repurchase mandates, a reverse share split authorization (1:10 ratio), and voting rights variations for Class B shares. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the reverse split authorization and voting rights changes are material governance matters affecting share structure and shareholder control.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-01
EX-99.1
The press release announces the signing of "definitive binding agreements for the joint venture development" of a 770-room Hotel101 in Bangkok, Thailand. This constitutes entry into a material acquisition or joint venture arrangement. The project is expected to generate approximately US$58 million in sales revenue and represents a significant milestone in the company's global expansion strategy, making it material to investors assessing the registrant's growth trajectory and capital deployment.
View raw filing on EDGAR →
6-K
Earnings release
confidence 25%
filed 2026-07-01
EX-99.1
This is a clinical trial results announcement for Namodenoson in a Phase 2a pancreatic cancer study. While it discloses positive safety and survival outcomes, it is not a financial earnings release (no quarterly or annual financial results). The disclosure is material to investors as it reports clinical progress on a key pipeline asset, but the event_type taxonomy does not contain a specific category for clinical trial results or product development milestones. This is an operational/strategic disclosure about drug development progress that does not fit neatly into the provided categories.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 1.01
INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-01
Item 7.01
The filing discloses positive Phase III results from an AI-driven drug discovery program with Yuva Biosciences, in which four small-molecule candidates demonstrated statistically significant ANT1 induction in human skeletal muscle cells. This represents a material operational and strategic milestone in the Company's drug development pipeline, supporting advancement to confirmatory testing. While not a traditional earnings release, M&A activity, or governance event, the disclosure of significant preclinical validation results for a lead development program is material to investors' assessment of the Company's pipeline progress and strategic direction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 3.02
SunPower closed a $10 million share exchange on July 1, 2026, whereby convertible note holders exchanged cash interest payments due on the notes for 19.3 million shares of common stock issued under Section 4(a)(2) exemption. This unregistered equity issuance materially restructures the company's capital obligations by converting future cash interest payments into equity, significantly diluting existing shareholders.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-01
EX-99.1
Park Ha Biological announced a formal membership application to the Personal Care Products Council (PCPC), described as "a pivotal step" and "a cornerstone of the Company's long-term globalization strategy" supporting its planned entry into Amazon North America. This is a material operational and strategic milestone—a regulatory/industry qualification event that directly enables the company's international expansion into a major market. While not a discrete transaction (M&A), it is a significant business development that would affect a reasonable investor's assessment of the company's ability to execute its North American growth strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-07-01
The filing's primary disclosure under Item 5.07 reports the results of Allarity's June 26, 2026 annual stockholders meeting, including voting outcomes on seven proposals (director election, auditor ratification, equity plan amendment, executive compensation advisory vote, share issuance approval, certificate amendment, and meeting adjournment). While Item 8.01 also discloses a USPTO patent grant for the stenoparib DRP® companion diagnostic, the 8-K structure and content center on the shareholder vote results as the material event triggering the filing.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 75%
filed 2026-07-01
EX-99.1
The press release announces a change in the ADS ratio from 1 ADS per 60 ordinary shares to 1 ADS per 1,800 ordinary shares, effective July 6, 2026. This is economically equivalent to a one-for-thirty reverse ADS split (or one-for-fifty reverse split depending on calculation method). While technically a capital restructuring rather than a traditional dividend, ADS ratio changes and reverse splits are classified under dividend_distribution in the taxonomy as they represent a return/restructuring of capital to shareholders. The announcement is material as it affects the trading price, outstanding share count, and CUSIP number of the security.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-01
EX-99.1
This press release announces a product demonstration of Wetour's Conductor neural wristband, showcasing real-time 3D hand pose decoding and gesture-to-text conversion capabilities. The disclosure highlights a material operational and strategic milestone — the advancement of the company's core Physical AI platform (Orchestra) with demonstrated technical capabilities that position it for enterprise deployment. While not a discrete M&A, financial, or governance event, the announcement of a significant product capability advancement and the opening of an enterprise Early Access Program would affect a reasonable investor's assessment of the company's technology maturity and commercial readiness.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-01
EX-99.1
This press release announces a 1-for-25 reverse split effective July 6, 2026, following shareholder authorization at the November 2025 Annual General Meeting and Board approval on June 4, 2026. While reverse splits are governance/capital structure actions, they are material to investors as they affect share count, trading price, and market perception. The disclosure is clearly governance-related but does not fit the specific named categories (exec appointment/departure, compensation, shareholder vote results, or auditor change), making governance_other the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-01
EX-99.1
NewcelX announced successful completion of a Type B Pre-IND meeting with the FDA, receiving constructive feedback and regulatory alignment on its development strategy for NCEL-101 in combination with tegoprubart for type 1 diabetes. This is a material regulatory milestone that clears the path toward IND-enabling activities and clinical trial initiation, representing significant progress in the company's lead program development. While not a discrete transaction (M&A), financial event, or governance matter, this regulatory achievement is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-01
The 6-K discloses a reverse stock split (1-for-3) approved by the Board on May 4, 2026, effective July 6, 2026, reducing outstanding Class A Ordinary Shares from 10,259,764 to approximately 3,419,922. This is a governance and capital structure event that materially affects share count, trading mechanics, and convertible securities adjustments. While not a named governance type (exec appointment/departure, compensation, shareholder vote results), it is clearly a governance/corporate action matter that would affect a reasonable investor's assessment of share ownership and market mechanics.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-01
The Company's Board approved a reverse stock split (1-for-15) effective July 6, 2026, explicitly stated as intended to "regain compliance with the Nasdaq $1.00 minimum bid price requirement." This disclosure indicates the Company had fallen below the minimum bid price threshold and faces delisting risk absent the reverse split. The timing and stated purpose directly signal a continued listing compliance issue.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-01
Item 1.01
Forum Markets entered into Side Letter Amendment No. 2 on June 30, 2026, amending the Series B-3 Preferred Stock Purchase Agreement with Zippy, Inc. This amendment materially restructures the payment and measurement framework for the "Final Make Whole Amount" from a single true-up date to a trifurcated framework with three separate measurement and payment dates (July 31, September 30, and December 31, 2026), with corresponding sell periods and cash payment obligations. While technically an amendment to an existing agreement rather than a new transaction, the filing is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), and the restructuring of payment obligations and stock consideration mechanics constitutes a material modification to the underlying strategic partnership and capital structure arrangement. The amendment affects the timing, measurement, and risk allocation of a significant financial obligation tied to the Company's stock performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-01
Item 1.01
Quantum Drones Corporation, a wholly owned subsidiary of Quantum Cyber N.V., entered into definitive agreements on June 26, 2026 to acquire substantially all assets of Arcade Technology LLC's metal stamping business, including real property and manufacturing equipment in Bridgeport, Connecticut, for aggregate consideration of $3.2 million. This acquisition represents a strategic transition from technology licensing to vertically integrated domestic manufacturing with control of production infrastructure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-01
Item 5.07
Stockholders approved two material amendments to Arogo's Certificate of Incorporation at a special meeting: extension of the business combination deadline from June 29, 2026 to June 29, 2028 (98.1% approval), and elimination of the prohibition on stockholder action via written consent (98.1% approval). The filing also discloses significant redemption activity of 18,664 shares, leaving only 5,731 publicly held shares outstanding.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-07-01
The filing's primary substantive disclosure is the execution of an Amended Settlement Agreement on June 22, 2026, to resolve a securities class action (Crivellaro v. Singularity Future Technology Ltd.) for $5.8 million in aggregate cash. This is a material litigation settlement that would affect a reasonable investor's assessment of the company's financial obligations and legal exposure. While Item 5.07 reports shareholder vote results (including director re-elections, auditor ratification, and approval of a reverse stock split and authorized shares increase), the Item 1.01 disclosure of the settlement agreement is the most material event disclosed in this filing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-07-01
Item 1.01
Resideo announced a planned spin-off of its ADI Global Distribution business into an independent, publicly traded company, with a record date of July 20, 2026 and expected distribution date of August 3, 2026. To finance the transaction, ADI Escrow Issuer LLC completed a $400 million senior notes offering on June 30, 2026, and Resideo entered into a credit agreement on July 1, 2026 providing $600 million term facility and $500 million revolving facility.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-01
Banco de Chile placed senior dematerialized bearer bonds (Serie FG) in the local Chilean market on July 1, 2026, for CLF 400,000 with maturity November 1, 2030, at an average rate of 2.82%. This is a creation of a new direct financial obligation and was filed as Material Information with the Chilean Financial Market Commission, meeting the definition of debt_issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
The 6-K discloses the closing of a private placement of 15,841,585 Class A ordinary shares at $1.01 per share for approximately $16.0 million in gross proceeds. This is an unregistered equity issuance under Regulation S, which is a dilutive capital raise. The disclosure explicitly references the subscription agreement and closing date (June 29, 2026), making this a completed dilutive issuance material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This is a clear disclosure of shareholder vote results from Advanced Biomed Inc.'s annual meeting held on June 30, 2026. The filing reports final tabulation of votes on five proposals: election of five directors, say-on-pay advisory vote, frequency of say-on-pay votes, auditor ratification, and meeting adjournment. All proposals passed with strong majorities. This is a quintessential Item 5.07 disclosure and is material to investors as it documents the outcome of fundamental governance matters including board composition and auditor approval.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-01
The 6-K discloses the appointment of Mr. Gang Liu as Chief Financial Officer of Chanson International Holding, effective immediately on June 26, 2026. While the report also mentions Ms. Jihong Cai's resignation as CFO on the same date, the principal disclosed action is the appointment of a named executive to a C-suite officer role. The filing includes Mr. Liu's extensive 30+ years of accounting and financial management experience and references employment and indemnification agreements, consistent with a material executive appointment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 1.01
On July 1, 2026, Actelis Networks entered into an Exchange and Amendment Agreement with White Lion Capital LLC to issue 9,850,000 shares of common stock (comprising direct shares, pre-funded warrants, and common warrants) in exchange for White Lion's rights under the original Common Stock Purchase Agreement. This unregistered private placement, relying on Section 4(a)(2) and Regulation D exemptions, represents substantial dilution to existing shareholders and was triggered by the Company's Nasdaq delisting in April 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Cadrenal Therapeutics completed a private placement of 960,000 shares of common stock (or pre-funded warrants), Series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions, raising $3.0 million in gross proceeds at $3.1249 per unit, with up to $5.8 million in additional potential proceeds from warrant exercises. The unregistered securities extend the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised) and are subject to registration rights obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
The filing discloses the completion of a material business combination on June 25, 2026, whereby SPAC Merger Sub merged with TLGY and Company Merger Sub merged with SC Assets, resulting in TLGY and SC Assets becoming wholly-owned subsidiaries of StablecoinX. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets" and describes the consummation of the Business Combination, including the exchange of shares and conversion of warrants. This is a change of control transaction material to any investor.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-07-01
EX-99.1
The announcement discloses receipt of approximately COP 1 trillion (~COP 0.8 trillion to Ecopetrol proper) in payment from the National Government for an outstanding account receivable from the Fuel Price Stabilization Fund (FEPC) for Q2 2025, settled via issuance of short-term Treasury Securities. This is a material financial event—a significant cash inflow and resolution of a major receivable—but does not fit the specific event-type taxonomy (not earnings, debt issuance, dividend, or impairment). It is clearly financial in nature and material to investor assessment of liquidity and working capital.
View raw filing on EDGAR →